Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Dronedarone

Nature Reviews Drug Discovery volume 8, pages 769–770 (2009)Cite this article

Abstract

In July 2009, dronedarone (Multaq; Sanofi–Aventis), an anti-arrhythmic agent, was approved by the US FDA to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Discovery of dronedarone.

References

  1. Page, R. L. & Roden, D. M. Drug therapy for atrial fibrillation: where do we go from here? Nature Rev. Drug Discov. 4, 899–910 (2005).

    Article  CAS  Google Scholar 

  2. Manning, A. et al. SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J. Cardiovasc. Pharmacol. 25, 252–261 (1995).

    Article  CAS  Google Scholar 

  3. Manning, A. S. et al. SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. J. Cardiovasc. Pharmacol. 26, 453–461 (1995).

    Article  CAS  Google Scholar 

  4. Finance, O. et al. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J. Cardiovasc. Pharmacol. 26, 570–576 (1995).

    Article  CAS  Google Scholar 

  5. Sun, W., Sarma, J. S. & Singh, B. N. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 100, 2276–2281 (1999).

    Article  CAS  Google Scholar 

  6. US Food and Drug Administration. FDA labelling information. FDA website [online], (2009).

  7. Singh, B. N. et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med. 357, 987–999 (2007).

    Article  CAS  Google Scholar 

  8. Hohnloser, S. H. et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360, 668–678 (2009).

    Article  CAS  Google Scholar 

  9. Kober, L. et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med. 358, 2678–2687 (2008).

    Article  Google Scholar 

  10. Roy, D. et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117, 1518–1525 (2008).

    Article  CAS  Google Scholar 

  11. Piccini, J. P. et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J. Am. Coll. Cardiol. 54, 1089–1095 (2009).

    Article  CAS  Google Scholar 

  12. Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation, N. Engl. J. Med. 30 Aug 2009 (doi: 10.1056/NEJMoa0905561).

    Article  CAS  Google Scholar 

  13. Connolly, S. J. et al. Analysis of stroke in a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter (ATHENA). Circulation (in the press).

  14. Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. J. Am. Med. Assoc. 285, 2370–2375 (2001).

    Article  CAS  Google Scholar 

  15. Coyne, K. S. et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 9, 348–356 (2006).

    Article  Google Scholar 

  16. IMS MIDAS, MAT Q1 2009 (IMS Health, 2009).

  17. Spencer, M. Amid restructuring, Sanofi gets FDA nod for heart drug. The Wall Street Journal 2 Jul 2009.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Richard L. Page is at the Division of Cardiology, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, Washington 98195-6422m, USA. RichardP@cardiology.washington.edu,

    Richard L. Page

  2. Bashar Hamad is at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK. bhamad@uk.imshealth.com,

    Bashar Hamad

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Richard L. Page
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bashar Hamad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

R.L.P. is currently an unpaid member of the steering committee for ATHENA, a clinical trial of dronedarone, which is sponsored by Sanofi-Aventis. He was previously a consultant with an honorarium paid for by Sanofi-Aventis and Astellas. He has had no competing financial interests since May 2008.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Page, R., Hamad, B. & Kirkpatrick, P. Dronedarone. Nat Rev Drug Discov 8, 769–770 (2009). https://doi.org/10.1038/nrd2998

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2998

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing